Literature DB >> 15464646

Misdiagnoses in children with dopa-responsive dystonia.

Mohammed M S Jan1.   

Abstract

Dystonia is a state of continuous contraction of groups of agonist and antagonist muscles resulting in a sustained abnormal posture. Dopa-responsive dystonia was first described in 1976 by Segawa. Patients typically have diurnal variation of their symptoms with worsening at the end of the day and a dramatic response to low-dose L-dopa. This report presents five consecutive children with dopa-responsive dystonia who were misdiagnosed initially as spastic diplegic cerebral palsy, intractable epilepsy, hereditary spastic paraplegia, or a neurodegenerative disorder. There were two males and three females aged 3-13 years (mean 8.6 years). They were monitored for up to 2 years (mean 14.8 months). One had focal, one axial, one segmental, and two generalized dystonia. The dystonia was paroxysmal in two (tiptoe walking and opisthotonus), and all had a progressive course. All children responded dramatically to L-dopa (mean 200 mg/day), including three who were wheelchair-bound for several years. The difficulties in early diagnosis, variability of clinical presentation, and dramatic response to L-dopa will be illustrated. To conclude, dopa-responsive dystonia should be considered in any child who presents with paroxysmal or progressive hypertonia of unknown etiology, because it responds so dramatically to L-dopa.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464646     DOI: 10.1016/j.pediatrneurol.2004.03.017

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  9 in total

Review 1.  Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Authors:  Joanne Ng; Apostolos Papandreou; Simon J Heales; Manju A Kurian
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 2.  Deep brain stimulation for dystonia: a novel perspective on the value of genetic testing.

Authors:  H A Jinnah; Ron Alterman; Christine Klein; Joachim K Krauss; Elena Moro; Marie Vidailhet; Robert Raike
Journal:  J Neural Transm (Vienna)       Date:  2017-02-03       Impact factor: 3.575

Review 3.  Neurological disorders presenting mainly in adolescence.

Authors:  S Macleod; R E Appleton
Journal:  Arch Dis Child       Date:  2007-02       Impact factor: 3.791

Review 4.  Delineation of the motor disorder of Lesch-Nyhan disease.

Authors:  H A Jinnah; Jasper E Visser; James C Harris; Alfonso Verdu; Laura Larovere; Irene Ceballos-Picot; Pedro Gonzalez-Alegre; Vladimir Neychev; Rosa J Torres; Olivier Dulac; Isabelle Desguerre; David J Schretlen; Kenneth L Robey; Gabor Barabas; Bastiaan R Bloem; William Nyhan; Raquel De Kremer; Gary E Eddey; Juan G Puig; Stephen G Reich
Journal:  Brain       Date:  2006-03-20       Impact factor: 13.501

Review 5.  Cerebral palsy: comprehensive review and update.

Authors:  Mohammed M S Jan
Journal:  Ann Saudi Med       Date:  2006 Mar-Apr       Impact factor: 1.526

6.  The Role of Neuroimaging and Genetic Analysis in the Diagnosis of Children With Cerebral Palsy.

Authors:  Veronka Horber; Ute Grasshoff; Elodie Sellier; Catherine Arnaud; Ingeborg Krägeloh-Mann; Kate Himmelmann
Journal:  Front Neurol       Date:  2021-02-09       Impact factor: 4.003

Review 7.  Childhood-onset hereditary spastic paraplegia and its treatable mimics.

Authors:  Darius Ebrahimi-Fakhari; Afshin Saffari; Phillip L Pearl
Journal:  Mol Genet Metab       Date:  2021-06-24       Impact factor: 4.797

Review 8.  Dystonic opisthotonus: a "red flag" for neurodegeneration with brain iron accumulation syndromes?

Authors:  Maria Stamelou; Scarlett C Lai; Annu Aggarwal; Susanne A Schneider; Henry Houlden; Tu-Hsueh Yeh; Amit Batla; Chin-Song Lu; Mohit Bhatt; Kailash P Bhatia
Journal:  Mov Disord       Date:  2013-06-04       Impact factor: 10.338

Review 9.  Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders.

Authors:  J Ng; S J R Heales; M A Kurian
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.